Sofosbuvir
1 NDC across 1 manufacturer|0 Generic,1 Brand
Sofosbuvir is used to treat chronic hepatitis c, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 6, 2013, and the first generic was approved Jan 27, 2022. In 2024, Medicare Part D spent $2 million on Sofosbuvir across 81 claims for 23 beneficiaries.
Sofosbuvir is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $975.30 to $975.30 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$975.30 – $975.30
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing SOFOSBUVIR
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SOVALDI 400 MG TABLET | $975.3000 per EA | — |
Frequently Asked Questions
What is Sofosbuvir used to treat?
Sofosbuvir is used to treat chronic hepatitis c, per the National Library of Medicine's MED-RT classification.
When did Sofosbuvir become available as a generic?
FDA approved the first generic Sofosbuvir (ANDA) on Jan 27, 2022.
How much does Medicare spend on Sofosbuvir?
In 2024, Medicare Part D spent $2 million on Sofosbuvir across 81 claims for 23 beneficiaries.
How many Sofosbuvir products are on the market?
The Sofosbuvir drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Sofosbuvir?
NADAC reference prices for Sofosbuvir range from $975.3000 to $975.3000 per EA.
Which manufacturers make Sofosbuvir?
1 manufacturer lists Sofosbuvir in NADAC. Ranked by number of NDCs, the largest are Gilead Sciences, Inc. (1).